Navigation Links
UofL research holds promise of therapeutic approach for gum disease
Date:3/27/2012

University of Louisville researchers are a step closer to eliminating periodontal disease through their work to develop synthetic molecules that prevent a bacteria responsible for the disease from spreading throughout the mouth.

The discovery could lead to the formulation of a mouth rinse, toothpaste or tooth varnish to prevent the pathogen from establishing itself orally.

Donald Demuth, PhD, associate dean for research and enterprise, UofL School of Dentistry, received a patent today for his work to develop peptides that inhibit the interaction between P. gingivalis and Streptococcus gordonii and prevent P. gingivalis colonization of the mouth. Peptides are molecules formed when two or more amino acids join together; they are the building blocks of proteins in a cell.

"When P. gingivalis enters the oral environment, it seeks out interaction with the bacterium S. gordonii an otherwise benign organism in order to lay the ground work to propagate and ultimately gain a foothold below the gum line, leading to periodontal disease.

"UofL Oral Health and Systemic Disease Group director Richard Lamont characterized this bacterial interaction and based on those studies, my team developed a series of peptides that prevent P. gingivalis and S. gordonii from coming together," Demuth said.

Demuth found that administering the peptide in an animal model prevented P. gingivalis related bone loss the clinical symptom of periodontal disease -- and prevented the spread of the bacterium in the mouth.

"This is one of the first examples of a potential targeted therapeutic approach that may control periodontal disease," he said.

Demuth is building his research through collaboration with Frederick Luzzio, PhD, professor, UofL College of Arts & Sciences, Department of Chemistry. They hope to further develop organic molecule structures that mimic the active peptides.

"The molecules must be potent and cost effective to manufacture. We know of no chemical technology on the market that targets specific oral pathogens, and this is an exciting endeavor," Luzzio said.

Luzzio and Demuth have a patent pending on certain discoveries related to this research. The investigators are working with the Office of Technology Transfer at UofL to find an industrial partner to license and commercialize the technology.


'/>"/>
Contact: Julie Heflin
julie.heflin@louisville.edu
502-852-7987
University of Louisville
Source:Eurekalert

Related biology news :

1. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
2. Researchers unravel genetic mechanism of fatty liver disease in obese children
3. UC research: Saving habitat key to songbirds survival
4. Montreal researchers repel mortality in Malian mothers
5. UF researchers look for ways to make an emerging technology safe for environment
6. Brandeis scientists win prestigious prize for circadian rhythms research
7. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
8. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
9. SDSCs big data expertise aiding genomics research
10. Young researcher taking fight against global killer to the next level in Vietnam
11. Space research institute honors Sen. Hutchison with Pioneer Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
Breaking Biology Technology: